- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07568730
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep 4 μM Ophthalmic Solution in Subjects With Neurotrophic Keratitis
Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The study will compare Lacripep 4 μM Ophthalmic Solution to vehicle ophthalmic solution for the treatment of Stage 1 neurotrophic keratitis (NK). Approximately 54 subjects will be enrolled and will enter a 2-week run-in period with open-label vehicle ophthalmic solution. At Visit 2 (Day 1; Baseline/Randomization), eligible subjects will be randomized to either Lacripep 4 μM Ophthalmic Solution or vehicle ophthalmic solution. Subjects will dose three times a day (TID) in both eyes (OU) for 8 weeks, with clinic visits at Week 2, Week 4, and Week 8.
A central reading center will assess study images to ensure objective, standardized, and unbiased grading.
At the Week 8 visit, subjects will be assigned to open-label treatment with Lacripep 4 μM Ophthalmic Solution for 4 weeks, through Week 12. The initiation of 4 weeks of open-label active treatment is designed to explore the potential effects of both a shorter and a longer treatment period: i.e., 4 weeks of active treatment for subjects originally randomized to vehicle ophthalmic solution, and 12 total weeks of active treatment for subjects originally randomized to Lacripep 4 μM Ophthalmic Solution. Subjects will continue to dose TID in both eyes.
All Week 1-8 treatment assignments will remain masked through database lock.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Marc Odrich, MD
- Telefoonnummer: 646.249.2800
- E-mail: modrich@tearsolutions.com
Studie Contact Back-up
- Naam: Michelle Carpenter
- E-mail: mcarpenter@rpspharma.com
Studie Locaties
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- University of South Florida
-
Contact:
- Study Coordinator
- Telefoonnummer: (813)974-0948
- E-mail: ssherous@usf.edu
-
-
Indiana
-
Carmel, Indiana, Verenigde Staten, 46032
- Werving
- Midwest Cornea Associates
-
Contact:
- Study Coordinator
- Telefoonnummer: 317-817-1765
- E-mail: mcaresearch@midwesteye.com
-
-
Massachusetts
-
Russells Mills, Massachusetts, Verenigde Staten, 02747
- Werving
- Eye Health Vision Center
-
Contact:
- Study Coordinator
- Telefoonnummer: 2105 508-994-1400
- E-mail: cfriedman@centuryvisionglobal.com
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55431
- Werving
- Minnesota Eye Consultants
-
Contact:
- Study Coordinator
- Telefoonnummer: 952.567.6111
- E-mail: aadreyer@mneye.com
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63131
- Nog niet aan het werven
- Ophthalmology Associates
-
Contact:
- Study Coordinator
- Telefoonnummer: 314-966-3377
- E-mail: samayatrawick@eyecare-partners.com
-
-
New York
-
New York, New York, Verenigde Staten, 10017
- Werving
- NYU Langone Center
-
Contact:
- Study Coordinator
- Telefoonnummer: 929-455-5522
- E-mail: Tonya.Robin@nyulangone.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Subjects who meet all the following inclusion criteria at Visit 1 (Screening) will be eligible to participate in the study.
-
Are ≥18 years of age.
-
Provide informed consent before any study-related procedures are performed.
-
Are willing and able to comply with study procedures and the study schedule.
-
Female subjects must either be incapable of pregnancy or must use an effective method of birth control for the duration of the study. Female subjects of childbearing potential must have a negative pregnancy test and not be nursing.
-
Have all of the following in at least one eye:
-
Stage 1 NK as defined by:
- Grade 3 cCFS using the National Eye Institute (NEI) scale (0-3 in one-point increments).
- Corneal sensitivity ≤4 cm in the central zone, as measured by Cochet-Bonnet aesthesiometer.
-
BCDVA +0.2 to +1.0 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent 20/32 to 20/200).
-
IOP ≤21 mmHg.
-
Exclusion Criteria:
Subjects who meet any of the following exclusion criteria at Visit 1 (Screening) will not be eligible to participate in the study. Ocular criteria apply to each eye independently, unless otherwise noted.
- Have received prior treatment with Lacripep Ophthalmic Solution or Oxervate® (cenegermin-bkbj) Ophthalmic Solution within 6 months prior to Visit 1 (Screening) and failed to demonstrate a clinically meaningful response, as determined by the Investigator.
- Have participated in a NK study within 90 days prior to Visit 1 (Screening).
- Have participated in any other clinical study or used an investigational agent within 30 days prior to Screening or plans to participate in another clinical study at any time during the conduct of this study.
- Have a glycated hemoglobin (HbA1c) score >9% within 90 days prior to Visit 1 (Screening).
- Have a history of or current conditions that may confound the study data; such conditions include but are not limited to ocular cicatricial pemphigoid, graft versus host disease, neuromyelitis optica, Stevens-Johnson syndrome, and Salzmann's nodular degeneration.
- Have an unstable history of severe systemic allergy or severe ocular allergy (including seasonal conjunctivitis expected during the study period) or chronic conjunctivitis and/or keratitis other than dry eye disease.
- Have been diagnosed with glaucoma or are a glaucoma suspect who requires or may require treatment during the study.
- Have, in the opinion of the Investigator, evidence of an active ocular infection (bacterial, viral, protozoal) in either eye.
- Have any intraocular inflammation (Tyndall score >0).
- Have, in the opinion of the Investigator, severe vision loss due to retinal disease, with no potential for visual improvement.
- Have an eyelid abnormality that may alter eyelid function; such abnormalities include but are not limited to blepharospasm, cerebrovascular accident, entropion, ectropion, and floppy lid syndrome.
- Have punctal occlusion or punctal plugs that will not be maintained during the study period.
- Have had any corneal surface procedure within 90 days prior to Visit 1 (Screening). This includes laser-assisted in situ keratomileusis (LASIK), phototherapeutic or photorefractive keratectomy (PTK or PRK), radial keratotomy (RK), small-incision lenticule extraction (SMILE), penetrating keratoplasty (PK), automated lamellar keratoplasty (ALK), deep anterior lamellar keratoplasty (DALK), Descemet membrane endothelial keratoplasty (DMEK), Descemet stripping endothelial keratoplasty (DSEK), superior limbic keratoconjunctivitis (SLK) surgery, and placement of any amniotic membrane.
- Have, in the opinion of the Investigator, NK that was induced by a neurosurgical procedure.
- Have undergone any other ocular surgery (including peripheral iridotomy (PI), laser iridotomy (LI) eyelid surgery and any surgical refractive procedures) within 90 days prior to Visit 1 (Screening) or expect to undergo ocular surgery during the study period.
- Have, in the opinion of the Investigator, history of viral corneal disease that resulted in significant corneal scarring.
- Have viral corneal disease without scarring that is considered unstable prior to Visit 1 (Screening), defined as discontinuation of topical ocular antiviral therapy or topical ocular steroid therapy within 2 weeks prior to Screening, or evidence of viral reactivation during the run-in period.
- Have received Botox (botulinum toxin) ocular injections to induce pharmacologic blepharoptosis within 45 days prior to Visit 1 (Screening).
- Have used any non-study issued eye drops or neurostimulators within 14 days prior to Visit 2 (Day 1; Baseline/Randomization).
- Anticipate a need to use therapeutic contact lenses or unwilling to discontinue wearing contact lenses for refractive correction during the study period.
- Have, in the opinion of the Investigator, an unstable medical condition that may confound the study data; such conditions include but are not limited to diabetes, thyroid disease, autoimmune disease, Parkinson's disease, and multiple sclerosis.
- Evidence of current drug or alcohol abuse or addiction, in the opinion of the Investigator.
- Are pregnant, nursing, or planning a pregnancy during the study period.
- Are an employee of a site directly involved in the management, administration, or support of the study or an immediate family member of the same.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Voertuig
|
Vehicle ophthalmic solution |
|
Experimenteel: Lacripep
|
Lacripep 4 μM Ophthalmic Solution |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary Efficacy
Tijdsspanne: Baseline to Week 8
|
Change from baseline in cCFS at Week 8 in Study Eye |
Baseline to Week 8
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary Efficacy
Tijdsspanne: Baseline to Week 8
|
Change from baseline in central corneal sensitivity at Week 8 in Study Eye |
Baseline to Week 8
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Marc Odrich, MD, TearSolutions CMO
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- TS-NK-001
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .